Plain-English translation of NCT06616571 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called QL0605, which is a growth factor injection designed to help your body maintain healthy white blood cells after chemotherapy. People receiving breast cancer chemotherapy are at risk of developing a dangerous condition where their white blood cell count drops too low, leaving them vulnerable to serious infections. This study will compare whether giving the medication 24 hours after chemotherapy or 48 hours after chemotherapy works better to prevent this complication.
Chemotherapy can severely lower white blood cell counts, making patients vulnerable to life-threatening infections. Doctors use growth factor medications to help rebuild these protective cells, but the best timing for giving this treatment after chemotherapy is not yet clear, so this trial will find out.
You likely qualify if…
You likely don't qualify if…
You would receive breast cancer chemotherapy as planned, and then be randomly assigned to receive the QL0605 injection either 24 hours or 48 hours after each chemotherapy cycle. The study will track your white blood cell counts, whether you develop infections, and any side effects like bone or muscle pain. You'll be monitored throughout your chemotherapy treatment to see how well this medication works at preventing low blood cell counts and serious infections.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Qilu Pharmaceutical Co., Ltd.
Enrollment target
~336 participants
Started
September 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mengli Zhu, Master
Qilu Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.